Waverley Pharma Inc.
Research Waverley Pharma Inc. (WAVE.V) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerWAVE.V
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Financial periodQ2 2026
- RevenueCAD 314.47K
- Net income-CAD 143.67K
- Free cash flow-CAD 82.03K
- Gross margin35.6%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 2.90M | -CAD 627.05K | -CAD 611.03K | 40.2% | n/a | CAD 44.95K | CAD 3.44M | -CAD 2.57M |
About Waverley Pharma Inc.
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Waverley Pharma Inc. do?
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.